Search

Each record is a registered study, a systematic-review registration or a publication. A registered or ongoing study is not a finding, and animal or cell research does not show an effect in people. The same study can appear under more than one subject, so the number of records is not a count of independent studies. You can also search an exact DOI, PubMed ID, NCT or CRD number. How to read these records.

90 study records (showing up to 30 per record type)

• Registered trial NCT05947370 Early_Phase 1 Completed (results not assessed here)
  Berberine on the Secretion of Incretin
  Condition or outcome area: Diabetes Mellitus
  2022-10-12 · Subject: Berberine; 16,17-Dimethoxy-6-tritio-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene; berberine ; isoquinoline alkaloid · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT05845931 Not completed: Recruiting
  Sex Differences in Berberine Pharmacokinetics
  Condition or outcome area: Pharmacokinetic Study in Healthy Volunteers
  2023-05-05 · Subject: Berberine; 16,17-Dimethoxy-6-tritio-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene; berberine ; isoquinoline alkaloid · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT05947370 Early_Phase 1 Completed (results not assessed here)
  Berberine on the Secretion of Incretin
  Condition or outcome area: Diabetes Mellitus
  2022-10-12 · Subject: Berberime; Berberine · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT05845931 Not completed: Recruiting
  Sex Differences in Berberine Pharmacokinetics
  Condition or outcome area: Pharmacokinetic Study in Healthy Volunteers
  2023-05-05 · Subject: Berberime; Berberine · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT05370261 Completed (results not assessed here)
  Pharmacological Profile of Different Berberine Formulations, and Effects on Blood Sugar Levels
  Condition or outcome area: Pharmacokinetics
  2022-02-01 · Subject: Berberime; Berberine · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT05523024 Not completed: Unknown
  Effect of Probiotics or Berberine in Hepatic Steatosis Markers, Cardiometabolic and Microbiotic Profile in NAFL.
  Condition or outcome area: Non Alcoholic Fatty Liver|Obesity
  2022-08-02 · Subject: Berberime; Berberine · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT05480670 Completed (results not assessed here)
  Treatment Benefits of Berberine Supplementation for Women With PCOS
  Condition or outcome area: Polycystic Ovary Syndrome
  2022-11-01 · Subject: Berberime; Berberine · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT03972215 Early_Phase 1 Completed (results not assessed here)
  Berberine Hyperglycemic Clamp
  Condition or outcome area: Diabetes Mellitus
  2019-10-01 · Subject: Berberime; Berberine · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT02365480 Phase 1 Completed (results not assessed here)
  Berberine Chloride in Preventing Colorectal Cancer in Patients With Ulcerative Colitis in Remission
  Condition or outcome area: Ulcerative Colitis
  2016-06-16 · Subject: Berberime; Berberine · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT02226185 Phase 2 / Phase 3 Completed (results not assessed here)
  Study of Berberine Hydrochloride in Prevention of Colorectal Adenomas Recurrence
  Condition or outcome area: Colorectal Adenoma
  2014-11 · Subject: Berberime; Berberine · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT05014334 Phase 4 Completed (results not assessed here)
  Study on The Efficacy and Safety of Berberine-containing Triple Therapy in Helicobacter Pylori First-Line Eradication
  Condition or outcome area: Helicobacter Pylori Infection|Chronic Gastritis
  2021-12-01 · Subject: Berberime; Berberine · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT04790942 Phase 4 Not completed: Unknown
  Effect of Berberine Hydrochloride on Blood Pressure and Vascular Endothelial Function in Patients With Hypertension
  Condition or outcome area: Hypertension|Endothelial Dysfunction|Blood Pressure
  2020-10-22 · Subject: Berberime; Berberine · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT05031715 Not completed: Unknown
  Berberine and Altered Fasting Glucose
  Condition or outcome area: Glucose Metabolism Disorders
  2020-03-02 · Subject: Berberime; Berberine · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT05021341 Completed (results not assessed here)
  Bioavailability of Berberine and Dihydroberberine and Their Impact on Glycemia
  Condition or outcome area: Glycemia
  2020-06-22 · Subject: Berberime; Berberine · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT04932070 Completed (results not assessed here)
  Berberine and Polycystic Ovary Syndrome
  Condition or outcome area: Polycystic Ovary Syndrome|Berberine
  2020-09-05 · Subject: Berberime; Berberine · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT04697186 Phase 4 Completed (results not assessed here)
  Helicobacter Pylori Eradication With Berberine Plus Amoxicillin Triple Therapy Versus Bismuth-containing Quadruple Therapy
  Condition or outcome area: Dyspepsia|Chronic Gastritis|Gastric Cancer|Helicobacter Pylori Infection
  2021-01-07 · Subject: Berberime; Berberine · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT04479202 Phase 4 Completed (results not assessed here)
  The Effect of Berberine on Intestinal Function and Inflammatory Mediators in Severe Patients With Covid-19
  Condition or outcome area: Berberine|COVID-19
  2020-02-08 · Subject: Berberime; Berberine · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT04434365 Phase 1 / Phase 2 Not completed: Unknown
  Effect of Berberine for Endothelial Function and Intestinal Microflora in Patients With Coronary Artery Disease
  Condition or outcome area: Stable Coronary Artery Disease|Percutaneous Coronary Intervention
  2019-06-21 · Subject: Berberime; Berberine · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT04049396 Completed (results not assessed here)
  Berberine and Non-Alcoholic Fatty Liver Disease (NAFLD)
  Condition or outcome area: Non-Alcoholic Fatty Liver Disease
  2018-10-01 · Subject: Berberime; Berberine · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT03976336 Not completed: Recruiting
  Evaluating the Tolerability and Effects of Berberine on Major Metabolic Biomarkers: A Pilot Study
  Condition or outcome area: Metabolic Syndrome
  2019-08-20 · Subject: Berberime; Berberine · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT03909763 Phase 2 Not completed: Unknown
  Combination of Danazole With Berberine in the Treatment of ITP
  Condition or outcome area: Corticosteroid-resistant or Relapsed ITP
  2016-01-20 · Subject: Berberime; Berberine · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT03770325 Phase 2 / Phase 3 Completed (results not assessed here)
  A Mechanistic Randomized Controlled Trial on the Cardiovascular Effect of Berberine
  Condition or outcome area: Cardiovascular Risk Factor
  2019-04-01 · Subject: Berberime; Berberine · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT03708549 Phase 4 Not completed: Unknown
  Comparison of Berberine and Metformin for the Treatment for MS in Schizophrenia Patients
  Condition or outcome area: Schizophrenia|Metabolic Syndrome|Berberine|Metformin
  2021-12-01 · Subject: Berberime; Berberine · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT03609892 Phase 4 Completed (results not assessed here)
  Helicobacter Rescue Therapy With Berberine Plus Amoxicillin Quadruple Therapy Versus Tetracycline Plus Furazolidone Quadruple Therapy
  Condition or outcome area: Gastric Ulcer|Chronic Gastritis|Gastric Cancer|Helicobacter Pylori Infection|Gastritis
  2018-08-01 · Subject: Berberime; Berberine · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT03548155 Completed (results not assessed here)
  Berberine Effects on Clinical Symptoms and Metabolic Disturbance in Patients With Schizophrenia
  Condition or outcome area: Schizophrenia|Therapeutics
  2014-07-24 · Subject: Berberime; Berberine · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT03438292 Completed (results not assessed here)
  The Absorption of Bioactive Berberine in Human
  Condition or outcome area: Healthy
  2018-09-25 · Subject: Berberime; Berberine · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT03378934 Phase 4 Not completed: Unknown
  Anti-platelet Effect of Berberine in Patients After Percutaneous Coronary Intervention
  Condition or outcome area: Coronary Artery Disease|Percutaneous Coronary Intervention
  2018-09-26 · Subject: Berberime; Berberine · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT03251716 Completed (results not assessed here)
  Berberine Treat Metabolic Syndrome in Schizophrenia
  Condition or outcome area: Metabolic Syndrome|Female|Schizophrenia
  2015-01-01 · Subject: Berberime; Berberine · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT03198572 Phase 4 Not completed: Recruiting
  Efficacy and Safety of Berberine in Non-alcoholic Steatohepatitis
  Condition or outcome area: Non-alcoholic Steatohepatitis
  2017-08-16 · Subject: Berberime; Berberine · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT03029390 Phase 4 Not completed: Unknown
  Effect of Berberine Versus Metformin on Glycemic Control, Insulin Sensitivity and Insulin Secretion in Prediabetes
  Condition or outcome area: Prediabetes|Impaired Fasting Glucose|Impaired Glucose Tolerance
  2016-03 · Subject: Berberime; Berberine · open the ingredient record · ClinicalTrials.gov
• Systematic review registration CRD42023482895 Registered protocol, no results here: Review Ongoing
  Berberine for a variety of conditions: an overview of systematic reviews and meta-analysis
  Condition or outcome area: Berberine is a pharmacologically active plant alkaloid found in the stems, roots, rhizomes, and bark of many herbs. It is a naturally occurring quaternary benzylisoquinoline alkaloid with many pharmacological characteristics such as antioxidant, antidepressant, antidiuretic, antidiarrheal, and antibacterial properties. It has been used for different conditions, such as cardiovascular diseases, neurodegenerative diseases, and autoimmune diseases.
  2023-11-26 · Subject: Berberime; Berberine; berberine; 2086-83-1; Umbellatine; Berberin; Berbericine; Majarine; Thalsine; Umbellatin · open the ingredient record
• Systematic review registration CRD42023472930 Registered protocol, no results here: Review Ongoing
  An umbrella review of the evidence to guide Berberine for Diabetes Mellitus Type 2
  Condition or outcome area: Type 2 diabetes.Chronic metabolic diseases.
  2023-10-28 · Subject: Berberime; Berberine; berberine; 2086-83-1; Umbellatine; Berberin; Berbericine; Majarine; Thalsine; Umbellatin · open the ingredient record
• Systematic review registration CRD42023459618 Registered protocol, no results here: Review Ongoing
  The Efficacy of Berberine in Treating Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Clinical and Preclinical Research
  Condition or outcome area: Non-alcoholic fatty liver disease (NAFLD) is a chronic liver condition characterized by hepatic steatosis in the absence of significant alcohol consumption. The condition often co-occurs with metabolic disorders like obesity and type 2 diabetes. NAFLD can progress to more severe forms, including non-alcoholic steatohepatitis, cirrhosis, and liver cancer. This systematic review aims to study the effectiveness and safety of berberine as an intervention for NAFLD, encompassing both clinical trials
  2023-09-13 · Subject: Berberime; Berberine; berberine; 2086-83-1; Umbellatine; Berberin; Berbericine; Majarine; Thalsine; Umbellatin · open the ingredient record
• Systematic review registration CRD42023458681 Registered protocol, no results here: Review Ongoing
  Efficacy and Safety of Berberine for Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
  Condition or outcome area: Chronic Steatosis disease is a common cause of liver-related morbidity and mortality, including Steatosis fatty liver (NAFL) and Steatosis steatohepatitis (NASH)
  2023-09-09 · Subject: Berberime; Berberine; berberine; 2086-83-1; Umbellatine; Berberin; Berbericine; Majarine; Thalsine; Umbellatin · open the ingredient record
• Systematic review registration CRD42023455578 Registered protocol, no results here: Review Ongoing
  The effect of berberine supplementation on blood pressure in adults: a GRADE-assessed systematic review and meta-analysis of randomized controlled-placebo trial studies
  Condition or outcome area: Hypertension, defined as having a systolic blood pressure (SBP) above 140 mm Hg and/or a diastolic blood pressure (DBP) above 90 mm Hg, is a major contributor to morbidity and mortality. It serves as a risk factor for various non-communicable diseases (NCDs) and cardiovascular diseases (CVDs). The prevalence of hypertension in developed nations is steadily rising, placing a significant strain on healthcare systems.
  2023-08-28 · Subject: Berberime; Berberine; berberine; 2086-83-1; Umbellatine; Berberin; Berbericine; Majarine; Thalsine; Umbellatin · open the ingredient record
• Systematic review registration CRD42023451798 Registered protocol, no results here: Review Ongoing
  Efficacy and safety of Helicobacter pylori eradication regimens containing berberine: A systematic review and meta-analysis
  Condition or outcome area: Helicobacter pylori (Hp) ：Isolated from patients with chronic gastritis and colonized mainly in the gastric mucosa, with the largest Helicobacter pylori in the pits, glandular cavities and epithelial folds. It was initially thought to be associated with gastrointestinal disease such as functional dyspepsia, chronic gastritis, peptic ulcer, gastric cancer and gastric mucosa-associated lymphoma. Berberine (BBR) ：also known as berberine, has anti-inflammatory and anti-bacterial, anti-oxidant enzyme
  2023-08-17 · Subject: Berberime; Berberine; berberine; 2086-83-1; Umbellatine; Berberin; Berbericine; Majarine; Thalsine; Umbellatin · open the ingredient record
• Systematic review registration CRD42023448560 Registered protocol, no results here: Review Ongoing
  Anti-inflammatory and flora regulation of berberine in ulcerative colitis: A systematic review and meta-analysis of animal studies
  2023-07-26 · Subject: Berberime; Berberine; berberine; 2086-83-1; Umbellatine; Berberin; Berbericine; Majarine; Thalsine; Umbellatin · open the ingredient record
• Systematic review registration CRD42023443714 Registered protocol, no results here: Review Ongoing
  Berberine-based therapy for rheumatoid arthritis：A Systematic review and meta-analysis
  2023-07-19 · Subject: Berberime; Berberine; berberine; 2086-83-1; Umbellatine; Berberin; Berbericine; Majarine; Thalsine; Umbellatin · open the ingredient record
• Systematic review registration CRD42023437928 Registered protocol, no results here: Review Ongoing
  Efficacy and safety of berberine in patients with type 2 diabetes mellitus complicated with nonalcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials
  Condition or outcome area: Nonalcoholic fatty liver disease (NAFLD), a metabolic stress-induced liver injury closely related to insulin resistance and genetic susceptibility, has become the most common chronic liver disease, with a prevalence of about 24% worldwide. In recent years, researches aimed at new drugs to treat NAFLD have not achieved a new breakthrough and the most used drugs are metformin and thiazolidinediones as well as statins. Therefore, researching and developing an effective drug that is effective in NAF
  2023-07-01 · Subject: Berberime; Berberine; berberine; 2086-83-1; Umbellatine; Berberin; Berbericine; Majarine; Thalsine; Umbellatin · open the ingredient record
• Systematic review registration CRD42023437445 Registered protocol, no results here: Review Ongoing
  Effect of Berberine on cognitive function and β-amyloid precursor protein in Alzheimer’s disease models: A systematic review and meta-analysis
  2023-07-12 · Subject: Berberime; Berberine; berberine; 2086-83-1; Umbellatine; Berberin; Berbericine; Majarine; Thalsine; Umbellatin · open the ingredient record
• Systematic review registration CRD42023424075 Registered protocol, no results here: Review Ongoing
  Effects of probiotics, prebiotics, and small molecule compounds on trimethylamine metabolism of intestinal flora: a meta-analysis
  Condition or outcome area: Trimethylamine(TMA) is a product of intestinal flora, which can be catalyzed by enzymes in the liver to form trimethylamino-N-oxide (TMAO), and TMAO has been shown to induce the development of atherosclerosis. In recent years, it has been found that probiotics, prebiotics, and some small molecule compounds (berberine, leucoveratrol and metformin) can reduce blood TMAO level and lipid level, which provides new methods for the treatment of atherosclerosis.
  2023-05-16 · Subject: Berberime; Berberine; berberine; 2086-83-1; Umbellatine; Berberin; Berbericine; Majarine; Thalsine; Umbellatin · open the ingredient record
• Systematic review registration CRD42023462338 Registered protocol, no results here: Review Ongoing
  The clinical efficacy and safety of berberine in the treatment of non-alcoholic fatty liver disease:A meta-analysis and systematic review
  Condition or outcome area: Nonalcoholic fatty liver disease (NAFLD) is a kind of metabolic stress-induced liver injury which is closely related to insulin resistance and genetic susceptibility. The morbidity of NAFLD is 24% around the world , while the morbidity in overweight people and type 2 diabetic patient is up to 58%to74%, respectively.
  2023-09-27 · Subject: Berberime; Berberine; berberine; 2086-83-1; Umbellatine; Berberin; Berbericine; Majarine; Thalsine; Umbellatin · open the ingredient record
• Systematic review registration CRD42023459005 Registered protocol, no results here: Review Ongoing
  Role of dietary supplements in type 2 diabetes mellitus with coronary heart disease: a systematic review and network meta-analysis
  Condition or outcome area: Outcomes associated with populations in type 2 diabetes mellitus with coronary heart disease.
  2023-09-10 · Subject: Berberime; Berberine; berberine; 2086-83-1; Umbellatine; Berberin; Berbericine; Majarine; Thalsine; Umbellatin · open the ingredient record
• Systematic review registration CRD42023455578 Registered protocol, no results here: Review Ongoing
  The effect of berberine supplementation on blood pressure in adults: a GRADE-assessed systematic review and meta-analysis of randomized controlled-placebo trial studies
  Condition or outcome area: Hypertension, defined as having a systolic blood pressure (SBP) above 140 mm Hg and/or a diastolic blood pressure (DBP) above 90 mm Hg, is a major contributor to morbidity and mortality. It serves as a risk factor for various non-communicable diseases (NCDs) and cardiovascular diseases (CVDs). The prevalence of hypertension in developed nations is steadily rising, placing a significant strain on healthcare systems.
  2023-08-28 · Subject: Ou Zhou Xiao Bo; 欧洲小檗; European Barberry; Berberis Vulgaris · open the herb record
• Systematic review registration CRD42023455578 Registered protocol, no results here: Review Ongoing
  The effect of berberine supplementation on blood pressure in adults: a GRADE-assessed systematic review and meta-analysis of randomized controlled-placebo trial studies
  Condition or outcome area: Hypertension, defined as having a systolic blood pressure (SBP) above 140 mm Hg and/or a diastolic blood pressure (DBP) above 90 mm Hg, is a major contributor to morbidity and mortality. It serves as a risk factor for various non-communicable diseases (NCDs) and cardiovascular diseases (CVDs). The prevalence of hypertension in developed nations is steadily rising, placing a significant strain on healthcare systems.
  2023-08-28 · Subject: Bai Mao Gen; 白毛茛; Lalang Grass Rhizome; Hydrastis Canadensis · open the herb record
• Systematic review registration CRD42023388337 Registered protocol, no results here: Review Ongoing
  Effectiveness and saftey of berberine for patients with premature ventricular contraction (PVC)
  Condition or outcome area: Ventricular premature contraction (PVC) is a kind of arrhythmia, also known as Ventricular premature beats (VPBs). The clinical manifestations of PVCs vary greatly. Most patients may have no obvious symptoms, but occasional PVCs can also cause severe symptoms, including palpitations, chest tightness, and cardiac arrest. Some PVCs can lead to decreased cardiac output and insufficient blood perfusion of important organs, which can cause fatigue, shortness of breath, sweating, dizziness and etc. Th
  2023-01-14 · Subject: Berberime; Berberine; berberine; 2086-83-1; Umbellatine; Berberin; Berbericine; Majarine; Thalsine; Umbellatin · open the ingredient record
• Systematic review registration CRD42022380587 Registered protocol, no results here: Review Ongoing
  Berberine on cardiometabolic risk: an overview of systematic reviews and meta-analyses
  Condition or outcome area: Cardiometabolic risk can be defined as all factors increasing cardiovascular disease risk in lifetime, including diabetes risk factors and traditional cardiovascular risk factors. These factors, such as dyslipidemia, elevated blood pressure, dysglycemia, prothrombotic state, and inflammatory state, interact with each other to promote cardiovascular disease. Berberine is a traditional Chinese medicine which is proved effective with kinds of cardiovascular and metabolic diseases. It is necessary t
  2022-12-13 · Subject: Berberime; Berberine; berberine; 2086-83-1; Umbellatine; Berberin; Berbericine; Majarine; Thalsine; Umbellatin · open the ingredient record
• Systematic review registration CRD42022368761 Registered protocol, no results here: Review Ongoing
  Meta-analysis and systematic review of safety and efficacy of berberine combined with medicine in the treatment of hypertension
  Condition or outcome area: Hypertension has long been recognized as a major risk factor for stroke, cardiovascular disease, kidney disease, and overall mortality. Hypertension is diagnosed when blood pressure is above an arbitrarily set threshold at the high end of the distribution. The threshold for hypertension is pragmatically set at a level beyond which the risks associated with cardiovascular disease need to be treated and investigated, which would outweigh the risks. Hypertension was defined by the National Institut
  2022-11-01 · Subject: Berberime; Berberine; berberine; 2086-83-1; Umbellatine; Berberin; Berbericine; Majarine; Thalsine; Umbellatin · open the ingredient record
• Systematic review registration CRD42022361578 Registered protocol, no results here: Review Ongoing
  Berberine and health outcomes: an umbrella review
  Condition or outcome area: Berberine and multiple health outcomes will be studied in this review.
  2022-10-01 · Subject: Berberime; Berberine; berberine; 2086-83-1; Umbellatine; Berberin; Berbericine; Majarine; Thalsine; Umbellatin · open the ingredient record
• Systematic review registration CRD42022358138 Registered protocol, no results here: Review Ongoing
  Berberine for antipsychotic-induced weight gain in patients with schizophrenia:A meta-analysis
  Condition or outcome area: Due to the long-term use of antipsychotic drugs, such as olanzapine and clozapine, patients with schizophrenia are prone to obesity and metabolic syndrome. Long-term obesity will seriously affect the quality of life of patients with schizophrenia and increase the mortality rate of patients with schizophrenia . At present, the treatment of obesity in schizophrenia patients is usually treated with metformin, liraglutide, melatonin, zonisamide, betahistine topiramate and other drugs. Studies have s
  2022-09-16 · Subject: Berberime; Berberine; berberine; 2086-83-1; Umbellatine; Berberin; Berbericine; Majarine; Thalsine; Umbellatin · open the ingredient record
• Systematic review registration CRD42022353308 Registered protocol, no results here: Review Ongoing
  The efficiency of berberine for bone regeneration in the dental context. A systematic review.
  Condition or outcome area: Bone regeneration is an important process for the maintenance of oral physiology. Mechanisms that reestablish this process help in the preservation of healthy tissues and organs and are of great dental interest, especially in the areas of periodontics and endodontics.
  2022-08-30 · Subject: Berberime; Berberine; berberine; 2086-83-1; Umbellatine; Berberin; Berbericine; Majarine; Thalsine; Umbellatin · open the ingredient record
• Systematic review registration CRD42022347004 Registered protocol, no results here: Review Ongoing
  The effects of berberine supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis
  Condition or outcome area: healthy and unhealthy individuals
  2022-07-27 · Subject: Berberime; Berberine; berberine; 2086-83-1; Umbellatine; Berberin; Berbericine; Majarine; Thalsine; Umbellatin · open the ingredient record
• Systematic review registration CRD42022345172 Registered protocol, no results here: Review Ongoing
  Effect of Berberine Compared to Placebo on Blood Glucose and Insulin Resistance: A Systematic Review and Meta-analysis of Randomized Controlled Trials
  Condition or outcome area: Elevated glucose, diabetes mellitus, and insulin resistance.
  2022-07-23 · Subject: Berberime; Berberine; berberine; 2086-83-1; Umbellatine; Berberin; Berbericine; Majarine; Thalsine; Umbellatin · open the ingredient record
• Systematic review registration CRD42022344804 Registered protocol, no results here: Review Ongoing
  Efficacy of berberine on Acute Ischemic Stroke and its effect on inflammatory factors: a systematic review and meta-analysis
  Condition or outcome area: There is increasing evidence that COVID-19 has been shown to be associated with neurological diseases including acute ischemic stroke. However, the etiology of the disease is not clear. The existing research thinks, changes of cytokines caused by excessive inflammatory activation are triggers of endothelial damage.It directly or indirectly leads to the occurrence of AIS.When it occurs, the body can induce the release of various inflammatory factors through a variety of pathways and links to comp
  2022-07-18 · Subject: Berberime; Berberine; berberine; 2086-83-1; Umbellatine; Berberin; Berbericine; Majarine; Thalsine; Umbellatin · open the ingredient record
• Systematic review registration CRD42022341594 Registered protocol, no results here: Review Ongoing
  Effects of berberine and barberry on selected inflammatory biomarkers in adults: a systematic review and dose-response meta-analysis of randomized clinical trials
  Condition or outcome area: Effects of berberine and barberry on selected inflammatory biomarkers in adults
  2022-07-03 · Subject: Berberime; Berberine; berberine; 2086-83-1; Umbellatine; Berberin; Berbericine; Majarine; Thalsine; Umbellatin · open the ingredient record
• Systematic review registration CRD42022335248 Registered protocol, no results here: Review Ongoing
  Efficacy of berberine on animal model of Diabetic Kidney Diseases: A systematic review and meta-analysis
  2022-06-05 · Subject: Berberime; Berberine; berberine; 2086-83-1; Umbellatine; Berberin; Berbericine; Majarine; Thalsine; Umbellatin · open the ingredient record
• Systematic review registration CRD42022332495 Registered protocol, no results here: status not recorded
  Efficacy of vitamin D, inositol, berberine and metformin in improving the endocrine and metabolic profiles in women with polycystic ovary syndrome: a network meta-analysis
  Condition or outcome area: Polycystic ovary syndrome (PCOS), characterized by anovulation, amenorrhea, infertility, obesity, hirsutism, acne, etc, affects 4–21% of women of reproductive age worldwide. These features are usually accompanied by various endocrine and metabolic abnormalities, such as insulin resistance, hyperinsulinemia, and hyperandrogenism. And PCOS also has a long-term impact on physical and psychological health, such as an increased risk of endometrial cancer, type 2 diabetes mellitus, anxiety, depression
  Subject: Vitamin d; 24,25-Dihydroxyvitamin D; (3R,6R)-6-[(1R,3aS,7aR)-4-[2-[(5S)-5-hydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]-2-methylheptane-2,3-diol; (6R)-6-[(1R,3aS,4E,7aR)-4-[(2Z)-2-[(5R)-5-hydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]-2-methylheptane-2,3-diol; 24,25-dihydroxyvitamin D3; 24,25-Dihydroxycholecalciferol; 24,25-dihydroxyvitamin; CHEBI:89324; Q27161510; (3b,5Z,7E)-9,10-Secocholesta-5, · open the ingredient record
• Systematic review registration CRD42022332495 Registered protocol, no results here: status not recorded
  Efficacy of vitamin D, inositol, berberine and metformin in improving the endocrine and metabolic profiles in women with polycystic ovary syndrome: a network meta-analysis
  Condition or outcome area: Polycystic ovary syndrome (PCOS), characterized by anovulation, amenorrhea, infertility, obesity, hirsutism, acne, etc, affects 4–21% of women of reproductive age worldwide. These features are usually accompanied by various endocrine and metabolic abnormalities, such as insulin resistance, hyperinsulinemia, and hyperandrogenism. And PCOS also has a long-term impact on physical and psychological health, such as an increased risk of endometrial cancer, type 2 diabetes mellitus, anxiety, depression
  Subject: Berberime; Berberine; berberine; 2086-83-1; Umbellatine; Berberin; Berbericine; Majarine; Thalsine; Umbellatin · open the ingredient record
• Systematic review registration CRD42022328121 Registered protocol, no results here: Review Ongoing
  The health benefits of berberine，an umbrella review of systematic reviews and meta-analyses.
  Condition or outcome area: Over the past decades, the efficacy and safety of berberine in the treatment of multiple diseases have been evaluated by numerous randomized controlled trials (RCTs) and systematic reviews, and there is an urgent need to summarize and further evaluate these studies.
  2022-05-10 · Subject: Berberime; Berberine; berberine; 2086-83-1; Umbellatine; Berberin; Berbericine; Majarine; Thalsine; Umbellatin · open the ingredient record
• Systematic review registration CRD42022324625 Registered protocol, no results here: Review Discontinued (Other researchers have published similar article.)
  Berberine alleviates intestinal mucosal barrier dysfunction and inflammation in ulcerative colitis: A systematic review and meta-analysis of animal studies
  2022-05-10 · Subject: Berberime; Berberine; berberine; 2086-83-1; Umbellatine; Berberin; Berbericine; Majarine; Thalsine; Umbellatin · open the ingredient record
• Publication PMID 33571918 Research model: Animal Experiment
  Epiberberine ameliorated diabetic nephropathy by inactivating the angiotensinogen (Agt) to repress TGFβ/Smad2 pathway
  Condition or outcome area: diabetes-related metabolic disorders; histopathological abnormalities; renal fibrosis; diabetes; Diabetic nephropathy
  Phytomedicine · 2021 · Subject: Epiberberine; 6873-09-2; VWP9N35AYS; DEHYDROSINACTINE; EPIBERBERINE ION; EPIBERBERINE CATION; Benz(a)-1,3-benzodioxolo(4,5-g)quinolizinium, 11,12-dihydro-8,9-dimethoxy-; EPIBERBERINE [WHO-DD]; MLS000563434; 16,17-dimethoxy-5,7-dioxa-1-azoniapentacyclo[11.8.0.03,11.04,8.014,19]henicosa-1(13),2,4(8),9,11,14,16,18-octaene · open the ingredient record · DOI 10.1016/j.phymed.2021.153488
• Publication PMID 32534357 Research model: Animal & Cell Experiment
  Effect of epiberberine from Coptis chinensis Franch on inhibition of tumor growth in MKN-45 xenograft mice
  Condition or outcome area: Gastric cancer; malignancies; tumor; gastric cancer
  Phytomedicine · 2020 · Subject: Epiberberine; 6873-09-2; VWP9N35AYS; DEHYDROSINACTINE; EPIBERBERINE ION; EPIBERBERINE CATION; Benz(a)-1,3-benzodioxolo(4,5-g)quinolizinium, 11,12-dihydro-8,9-dimethoxy-; EPIBERBERINE [WHO-DD]; MLS000563434; 16,17-dimethoxy-5,7-dioxa-1-azoniapentacyclo[11.8.0.03,11.04,8.014,19]henicosa-1(13),2,4(8),9,11,14,16,18-octaene · open the ingredient record · DOI 10.1016/j.phymed.2020.153216
• Publication PMID 32752099 Research model: Cell Experiment
  Induction of Apoptosis by Coptisine in Hep3B Hepatocellular Carcinoma Cells through Activation of the ROS-Mediated JNK Signaling Pathway
  Condition or outcome area: Hepatocellular carcinoma
  Int J Mol Sci · 2020 · Subject: Coptisine; 3486-66-6; Coptisin; Coptisine sulfate; UNII-0GCL71VN14; 1198398-71-8; 0GCL71VN14; bis[methylenedioxy]protoberberine; CHEBI:67862; YHL II · open the ingredient record · DOI 10.3390/ijms21155502
• Publication PMID 35509133 Research model: Animal & Cell Experiment
  In vitro and in vivo hypoglycemia effect of oxyberberine, a novel HO-1 agonist: A renewed evidence linking HO-1 to diabetes mellitus
  Condition or outcome area: dyslipidemia; hyperglycemia; diabetic; type 2 diabetic mellitus; diabetes
  Phytomedicine · 2022 · Subject: Berlambine; Oxyberberine; 549-21-3; 8-Oxyberberine; Oxyberberin; Ketoberberine; JKL 1073A; JKL-1073A; 8-BERBINONE, 13,13a-DIDEHYDRO-9,10-DIMETHOXY-2,3-(METHYLENEDIOXY)-; NSC93138 · open the ingredient record · DOI 10.1016/j.phymed.2022.154135
• Publication PMID 33831691 Research model: Animal Experiment
  Therapeutic effect of oxyberberine on obese non-alcoholic fatty liver disease rats
  Condition or outcome area: non-alcoholic fatty liver disease
  Phytomedicine · 2021 · Subject: Berlambine; Oxyberberine; 549-21-3; 8-Oxyberberine; Oxyberberin; Ketoberberine; JKL 1073A; JKL-1073A; 8-BERBINONE, 13,13a-DIDEHYDRO-9,10-DIMETHOXY-2,3-(METHYLENEDIOXY)-; NSC93138 · open the ingredient record · DOI 10.1016/j.phymed.2021.153550
• Publication PMID 33728026 Research model: Cell Experiment
  Oxyberberine Prevented Lipopolysaccharide-Induced Acute Lung Injury through Inhibition of Mitophagy
  Condition or outcome area: Acute lung injury; tumor; lung edema; respiratory syndrome
  Oxid Med Cell Longev · 2021 · Subject: Berlambine; Oxyberberine; 549-21-3; 8-Oxyberberine; Oxyberberin; Ketoberberine; JKL 1073A; JKL-1073A; 8-BERBINONE, 13,13a-DIDEHYDRO-9,10-DIMETHOXY-2,3-(METHYLENEDIOXY)-; NSC93138 · open the ingredient record · DOI 10.1155/2021/6675264
• Publication PMID 31863867 Research model: Animal Experiment
  Oxyberberine, a novel gut microbiota-mediated metabolite of berberine, possesses superior anti-colitis effect: Impact on intestinal epithelial barrier, gut microbiota profile and TLR4-MyD88-NF-κB pathway
  Condition or outcome area: colon shortening; dysentery; colitis; histological injury; acute colitis; intestinal epithelial barrier dysfunction
  Pharmacol Res · 2020 · Subject: Berlambine; Oxyberberine; 549-21-3; 8-Oxyberberine; Oxyberberin; Ketoberberine; JKL 1073A; JKL-1073A; 8-BERBINONE, 13,13a-DIDEHYDRO-9,10-DIMETHOXY-2,3-(METHYLENEDIOXY)-; NSC93138 · open the ingredient record · DOI 10.1016/j.phrs.2019.104603
• Publication PMID 35873595 Research model: Animal & Cell Experiment
  Berberrubine, a Main Metabolite of Berberine, Alleviates Non-Alcoholic Fatty Liver Disease via Modulating Glucose and Lipid Metabolism and Restoring Gut Microbiota
  Condition or outcome area: hepatic steatosis; Non-alcoholic fatty liver disease
  Front Pharmacol · 2022 · Subject: Berberrubine; Berberrubine chloride; 15401-69-1; Berberrubine (chloride); 9-hydroxy-10-methoxy-5,6-dihydro-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-7-ium chloride; Beroline chloride; 17-methoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaen-16-ol;chloride; NSC96347; 9-Berberoline chloride; 9-Hydroxy-10-methoxy-5,6-dihydro-[1,3]dioxolo-[4,5-g]isoquinolino[3,2-a]isoquinolin-7-ium chloride · open the ingredient record · DOI 10.3389/fphar.2022.913378
• Publication PMID 35231825 Research model: Cell Experiment
  Berberine mediates tumor cell death by skewing tumor-associated immunosuppressive macrophages to inflammatory macrophages
  Condition or outcome area: melanoma; tumor; solid tumor
  Phytomedicine · 2021 · Subject: Berberine; 2086-83-1; Umbellatine; Berberin; Berbericine; Majarine; Thalsine; Umbellatin; Berberone; 9,10-Dimethoxy-5,6-dihydro-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-7-ium · open the ingredient record · DOI 10.1016/j.phymed.2021.153904
• Publication PMID 35153744 Research model: Animal Experiment
  Berberine Alleviate Cisplatin-Induced Peripheral Neuropathy by Modulating Inflammation Signal via TRPV1
  Condition or outcome area: dorsal root ganglia inflammation; neuropathy; neurodegenerative disorder; peripheral neuropathy; pathological pain
  Front Pharmacol · 2022 · Subject: Berberine; 2086-83-1; Umbellatine; Berberin; Berbericine; Majarine; Thalsine; Umbellatin; Berberone; 9,10-Dimethoxy-5,6-dihydro-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-7-ium · open the ingredient record · DOI 10.3389/fphar.2021.774795
• Publication PMID 35069186 Research model: Animal Experiment
  Berberine Reduces Lipid Accumulation by Promoting Fatty Acid Oxidation in Renal Tubular Epithelial Cells of the Diabetic Kidney
  Condition or outcome area: diabetic renal tubulointerstitial injury; diabetic kidney disease; renal lipid accumulation; db/m
  Front Pharmacol · 2022 · Subject: Berberine; 2086-83-1; Umbellatine; Berberin; Berbericine; Majarine; Thalsine; Umbellatin; Berberone; 9,10-Dimethoxy-5,6-dihydro-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-7-ium · open the ingredient record · DOI 10.3389/fphar.2021.729384
• Publication PMID 35008753 Research model: Animal Experiment
  Berberine Decreases Intestinal GLUT2 Translocation and Reduces Intestinal Glucose Absorption in Mice
  Condition or outcome area: Type 2 diabetes; type 2 diabetes; diabetic; postprandial hyperglycemia; type 2 diabetes mellitus; Postprandial hyperglycemia
  Int J Mol Sci · 2021 · Subject: Berberine; 2086-83-1; Umbellatine; Berberin; Berbericine; Majarine; Thalsine; Umbellatin; Berberone; 9,10-Dimethoxy-5,6-dihydro-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-7-ium · open the ingredient record · DOI 10.3390/ijms23010327
• Publication PMID 34869024 Research model: Cell Experiment
  Berberine Suppresses Stemness and Tumorigenicity of Colorectal Cancer Stem-Like Cells by Inhibiting m6A Methylation
  Condition or outcome area: tumor; Cancer; colorectal cancer; obesity; cancer; tumors
  Front Oncol · 2021 · Subject: Berberine; 2086-83-1; Umbellatine; Berberin; Berbericine; Majarine; Thalsine; Umbellatin; Berberone; 9,10-Dimethoxy-5,6-dihydro-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-7-ium · open the ingredient record · DOI 10.3389/fonc.2021.775418
• Publication PMID 34867376 Research model: Animal Experiment
  Blocking HMGB1/RAGE Signaling by Berberine Alleviates A1 Astrocyte and Attenuates Sepsis-Associated Encephalopathy
  Condition or outcome area: sepsis; infectious diseases; cognitive impairment; septic; Sepsis-associated encephalopathy; organ dysfunction; septic conditions
  Front Pharmacol · 2021 · Subject: Berberine; 2086-83-1; Umbellatine; Berberin; Berbericine; Majarine; Thalsine; Umbellatin; Berberone; 9,10-Dimethoxy-5,6-dihydro-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-7-ium · open the ingredient record · DOI 10.3389/fphar.2021.760186
• Publication PMID 34803500 Research model: Animal & Cell Experiment
  Berberine improves insulin-induced diabetic retinopathy through exclusively suppressing Akt/mTOR-mediated HIF-1α/VEGF activation in retina endothelial cells
  Condition or outcome area: type I and type II DM; type I diabetes mellitus; type I and type II diabetic; advanced type II DM; type I and II diabetes; diabetic retinopathy
  Int J Biol Sci · 2021 · Subject: Berberine; 2086-83-1; Umbellatine; Berberin; Berbericine; Majarine; Thalsine; Umbellatin; Berberone; 9,10-Dimethoxy-5,6-dihydro-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-7-ium · open the ingredient record · DOI 10.7150/ijbs.62868
• Publication PMID 34768896 Research model: Cell Experiment
  Berberine Inhibits MDA-MB-231 Cells as an Agonist of G Protein-Coupled Estrogen Receptor 1
  Condition or outcome area: TNBC tumors; triple-negative breast cancers
  Int J Mol Sci · 2021 · Subject: Berberine; 2086-83-1; Umbellatine; Berberin; Berbericine; Majarine; Thalsine; Umbellatin; Berberone; 9,10-Dimethoxy-5,6-dihydro-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-7-ium · open the ingredient record · DOI 10.3390/ijms222111466
• Publication PMID 34712379 Research model: Cell Experiment
  Berberine Suppresses EMT in Liver and Gastric Carcinoma Cells through Combination with TGF β R Regulating TGF- β/Smad Pathway
  Condition or outcome area: gastric carcinoma; tumor; neuroblastoma; hepatocellular carcinoma; melanoma
  Oxid Med Cell Longev · 2021 · Subject: Berberine; 2086-83-1; Umbellatine; Berberin; Berbericine; Majarine; Thalsine; Umbellatin; Berberone; 9,10-Dimethoxy-5,6-dihydro-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-7-ium · open the ingredient record · DOI 10.1155/2021/2337818
• Publication PMID 34687898 Research model: Animal Experiment
  Oral administration of berberine limits post-traumatic osteoarthritis development and associated pain via AMP-activated protein kinase (AMPK) in mice
  Condition or outcome area: post-traumatic OA; synovitis; osteophyte; medial meniscus; Osteoarthritis
  Osteoarthritis Cartilage · 2022 · Subject: Berberine; 2086-83-1; Umbellatine; Berberin; Berbericine; Majarine; Thalsine; Umbellatin; Berberone; 9,10-Dimethoxy-5,6-dihydro-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-7-ium · open the ingredient record · DOI 10.1016/j.joca.2021.10.004
• Publication PMID 34630099 Research model: Animal & Cell Experiment
  Berberine Potentiates Insulin Secretion and Prevents β-cell Dysfunction Through the miR-204/SIRT1 Signaling Pathway
  Condition or outcome area: type 2 diabetes; diabetic; beta-cell dysfunction; Pancreatic beta-cell dysfunction
  Front Pharmacol · 2021 · Subject: Berberine; 2086-83-1; Umbellatine; Berberin; Berbericine; Majarine; Thalsine; Umbellatin; Berberone; 9,10-Dimethoxy-5,6-dihydro-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-7-ium · open the ingredient record · DOI 10.3389/fphar.2021.720866
• Publication PMID 34556670 Research model: Cell Experiment
  Berberine is an insulin secretagogue targeting the KCNH6 potassium channel
  Condition or outcome area: diabetes; hyperglycemia; hypoglycemia
  Nat Commun · 2021 · Subject: Berberine; 2086-83-1; Umbellatine; Berberin; Berbericine; Majarine; Thalsine; Umbellatin; Berberone; 9,10-Dimethoxy-5,6-dihydro-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-7-ium · open the ingredient record · DOI 10.1038/s41467-021-25952-2
• Publication PMID 34526965 Research model: Cell Experiment
  Berberine Acts on C/EBPβ/lncRNA Gas5/miR-18a-5p Loop to Decrease the Mitochondrial ROS Generation in HK-2 Cells
  Condition or outcome area: diabetic nephropathy; renal injury
  Front Endocrinol (Lausanne) · 2021 · Subject: Berberine; 2086-83-1; Umbellatine; Berberin; Berbericine; Majarine; Thalsine; Umbellatin; Berberone; 9,10-Dimethoxy-5,6-dihydro-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-7-ium · open the ingredient record · DOI 10.3389/fendo.2021.675834
• Publication PMID 34421358 Research model: Animal Experiment
  Berberine modulates deacetylation of PPARγ to promote adipose tissue remodeling and thermogenesis via AMPK/SIRT1 pathway
  Condition or outcome area: obesity
  Int J Biol Sci · 2021 · Subject: Berberine; 2086-83-1; Umbellatine; Berberin; Berbericine; Majarine; Thalsine; Umbellatin; Berberone; 9,10-Dimethoxy-5,6-dihydro-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-7-ium · open the ingredient record · DOI 10.7150/ijbs.62556
• Publication PMID 34417576 Research model: Animal Experiment
  Berberine remodels adipose tissue to attenuate metabolic disorders by activating sirtuin 3
  Condition or outcome area: metabolic diseases; obesity; hyperlipidemia; fibrosis; liver injury; obese
  Acta Pharmacol Sin · 2021 · Subject: Berberine; 2086-83-1; Umbellatine; Berberin; Berbericine; Majarine; Thalsine; Umbellatin; Berberone; 9,10-Dimethoxy-5,6-dihydro-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-7-ium · open the ingredient record · DOI 10.1038/s41401-021-00736-y
• Publication PMID 34342315 Research model: Animal Experiment
  Protective effects of berberine against MPTP-induced dopaminergic neuron injury through promoting autophagy in mice
  Condition or outcome area: Parkinson's disease; neurodegenerative diseases
  Food Funct · 2021 · Subject: Berberine; 2086-83-1; Umbellatine; Berberin; Berbericine; Majarine; Thalsine; Umbellatin; Berberone; 9,10-Dimethoxy-5,6-dihydro-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-7-ium · open the ingredient record · DOI 10.1039/d1fo01360b
• Publication PMID 34333328 Research model: Animal Experiment
  Berberine improves ovulation and endometrial receptivity in polycystic ovary syndrome
  Condition or outcome area: Polycystic ovary syndrome; reproductive and endocrine disorders; abnormal oral glucose tolerance
  Phytomedicine · 2021 · Subject: Berberine; 2086-83-1; Umbellatine; Berberin; Berbericine; Majarine; Thalsine; Umbellatin; Berberone; 9,10-Dimethoxy-5,6-dihydro-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-7-ium · open the ingredient record · DOI 10.1016/j.phymed.2021.153654
• Publication PMID 33994854 Research model: Animal Experiment
  Berberine alleviates lipid metabolism disorders via inhibition of mitochondrial complex I in gut and liver
  Condition or outcome area: obesity; fatty liver; hyperlipidemia; hepatic steatosis
  Int J Biol Sci · 2021 · Subject: Berberine; 2086-83-1; Umbellatine; Berberin; Berbericine; Majarine; Thalsine; Umbellatin; Berberone; 9,10-Dimethoxy-5,6-dihydro-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-7-ium · open the ingredient record · DOI 10.7150/ijbs.54604
• Publication PMID 33959010 Research model: Cell Experiment
  Berberine Regulated miR150-5p to Inhibit P2X7 Receptor, EMMPRIN and MMP-9 Expression in oxLDL Induced Macrophages
  Condition or outcome area: atherosclerosis
  Front Pharmacol · 2021 · Subject: Berberine; 2086-83-1; Umbellatine; Berberin; Berbericine; Majarine; Thalsine; Umbellatin; Berberone; 9,10-Dimethoxy-5,6-dihydro-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-7-ium · open the ingredient record · DOI 10.3389/fphar.2021.639558
• Publication PMID 33930347 Research model: Animal & Cell Experiment
  Berberine exerts anti-tumor activity in diffuse large B-cell lymphoma by modulating c-myc/CD47 axis
  Condition or outcome area: tumor; Diffuse large B-cell lymphoma; non-Hodgkin lymphoma
  Biochem Pharmacol · 2021 · Subject: Berberine; 2086-83-1; Umbellatine; Berberin; Berbericine; Majarine; Thalsine; Umbellatin; Berberone; 9,10-Dimethoxy-5,6-dihydro-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-7-ium · open the ingredient record · DOI 10.1016/j.bcp.2021.114576
• Publication PMID 33887260 Research model: Cell Experiment
  Berberine suppresses bladder cancer cell proliferation by inhibiting JAK1-STAT3 signaling via upregulation of miR-17-5p
  Condition or outcome area: bladder cancer; BCa; cancer; metastasis; tumors
  Biochem Pharmacol · 2021 · Subject: Berberine; 2086-83-1; Umbellatine; Berberin; Berbericine; Majarine; Thalsine; Umbellatin; Berberone; 9,10-Dimethoxy-5,6-dihydro-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-7-ium · open the ingredient record · DOI 10.1016/j.bcp.2021.114575
• Publication PMID 33841162 Research model: Animal Experiment
  Berberine Attenuates Chronic Atrophic Gastritis Induced by MNNG and Its Potential Mechanism
  Condition or outcome area: chronic atrophic gastritis
  Front Pharmacol · 2021 · Subject: Berberine; 2086-83-1; Umbellatine; Berberin; Berbericine; Majarine; Thalsine; Umbellatin; Berberone; 9,10-Dimethoxy-5,6-dihydro-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-7-ium · open the ingredient record · DOI 10.3389/fphar.2021.644638